Sesaren

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sesaren

Property Description
Active Ingredient Venlafaxine
Form Oral tablets, Extended-release capsules
Pharmacological Class Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
Common Use Stabilization of mood and emotional resilience
Origin Synthetic, bicyclic phenylethylamine compound

What Type of Medicine is Sesaren?

Sesaren is a prescription-only medication classified as an antidepressant and belongs specifically to the Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) pharmacological class. As an SNRI, the drug is designed to affect two key neurotransmitters (Serotonin and Norepinephrine) in the brain. The dual-action mechanism of the SNRI class sets it apart from other drug classes, offering a broader approach to influencing neurochemical pathways. Venlafaxine is clinically recognized for its dose-dependent influence on norepinephrine reuptake.


Composition and Available Forms of Venlafaxine

The active ingredient in Sesaren is Venlafaxine, which is a synthetic compound classified chemically as a bicyclic phenylethylamine. This substance is typically administered as a salt, such as Venlafaxine hydrochloride. As an oral medication, Sesaren is available in solid dosage forms, including tablets and capsules. Crucially, it is formulated for both immediate-release and the more common extended-release use. The extended-release version is a long-acting option that is designed to provide a slower, more consistent release of the active ingredient into the bloodstream throughout the day, which simplifies the administration schedule.


Sesaren's General Therapeutic Purpose

The fundamental action of Sesaren is to support and restore neurotransmitter balance by blocking the reabsorption, or "reuptake," of Serotonin and Norepinephrine into nerve cells. By inhibiting this process, the drug increases the concentration of these essential chemical messengers available to communicate within the brain, thereby enhancing their regulatory effects. Venlafaxine is recognized for its efficacy as a treatment targeting these specific neurotransmitter systems. For a patient, this means the medication is intended to gradually stabilize mood, enhance overall emotional resilience, and reduce the severity of excessive worry, such as in the context of generalized anxiety.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Sesaren?

Possible Side Effects and Safety Information

The safety profile of Sesaren (Venlafaxine) is structured by governmental regulatory documents to classify adverse reactions based on their frequency and the physiological system affected. The incidence of effects is officially classified into tiers, such as very common, common, uncommon, and rare, reflecting observations from clinical studies. Effects are also grouped into systems like Gastrointestinal disorders, Nervous system disorders, and Cardiac disorders.

Reactions classified as very common include nausea, dry mouth, headache, and dizziness. Common reactions often involve constipation, hypertension (elevated blood pressure), and sleep disturbances such as somnolence or insomnia. These frequency classifications establish the regulatory understanding of expected risk.

Officially documented serious adverse reactions include the risk of Serotonin Syndrome, a potentially life-threatening condition, and a noted risk of Suicidal Thoughts and Behaviors, especially in young adults during the initial months of therapy. Other serious concerns mentioned in regulatory labeling include sustained Hypertension, Abnormal Bleeding events, and the potential to precipitate Angle-Closure Glaucoma.

Safety notes for specific populations exist, such as the increased caution advised for patients with hepatic (liver) or renal (kidney) impairment due to reduced clearance. The label notes that abrupt cessation or reduction of the medicine may lead to discontinuation symptoms. Use is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the heightened risk of serious reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation details the documented clinical manifestations and required emergency actions for an overdose of Sesaren (Venlafaxine). Overdose may present with signs such as tachycardia (increased heart rate), somnolence (drowsiness), mydriasis (pupil dilation), vertigo, and Electrocardiogram (ECG) changes.

Regulatory sources classify potential severe or life-threatening outcomes, including Serotonin Syndrome, convulsions (seizures), coma, and Ventricular Tachycardia. Fatal outcomes have been reported, particularly in cases where the drug was ingested in combination with other substances or alcohol.

Immediate medical attention must be sought for any suspected overdosage. The official guidance requires contacting emergency services immediately for severe manifestations or if loss of consciousness occurs.

No specific antidote is known for Venlafaxine, as stated in the prescribing information. Therefore, management is limited to officially described symptomatic and supportive treatment, which may include airway management, cardiac monitoring, and procedures such as gastric lavage or the use of activated charcoal, based on the medical professional's assessment and regulatory protocols. Continuous monitoring of vital signs and clinical status is necessary.

Therapeutic Uses of Sesaren

What Sesaren Treats: Main Uses and Benefits

Sesaren (Venlafaxine) is applied in psychiatric care across several core conditions, providing supportive relief that helps ease the overall symptom burden. It is used to manage a range of conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). It is commonly used when supportive symptom management is appropriate to address symptom clusters that may become intense or disruptive.

The medication is applied across domains where additional symptomatic support is needed, relevant for managing symptoms that interfere with daily comfort, such as pervasive low mood, excessive worrying, and debilitating fear. Offering symptomatic relief assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations during periods of heightened discomfort.

“The medication is considered relevant for easing the overall symptom load and contributing to improved comfort during symptomatic periods.”


Quick Fact: Support for Pervasive Low Mood Sesaren helps address core emotional and cognitive symptoms, including profound sadness and the loss of interest or pleasure (anhedonia), which are often seen in conditions characterized by periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Sesaren (Venlafaxine) is strictly defined by regulatory guidelines based on age, concurrent medications, organ function, and pre-existing medical conditions.

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

  • Patients with known hypersensitivity to venlafaxine or any component of the formulation.
  • Patients requiring concomitant use of Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI (including intravenous Methylene Blue or Linezolid).

Age-Group and Organ Function Eligibility

Eligibility Classification Population Group Regulatory Status
Approved Use Adults (18 years and older) Established
Use Not Recommended Pediatric patients (under 18) Not approved or not recommended
Restricted Use Severe Renal or Hepatic Impairment Requires a mandatory dose reduction

Conditional Eligibility and Special Considerations

Use of Sesaren requires caution or pre-treatment screening in individuals with specific histories or conditions. These include patients with a history of bipolar disorder or mania, as the drug may activate these conditions. Patients with uncontrolled hypertension must have their blood pressure managed before treatment initiation. Use during pregnancy (especially the third trimester) and lactation requires careful consideration due to documented risks to the neonate.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Sesaren (Venlafaxine) is structured around two primary concerns: pharmacodynamic risk and pharmacokinetic exposure alteration. Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, is strictly contraindicated due to the high, life-threatening risk of serotonin syndrome. Regulatory mandates require a specific washout period of 7 to 14 days when transitioning between Sesaren and an MAOI.

Another significant pharmacodynamic interaction involves substances that interfere with hemostasis, such as Warfarin and NSAIDs, which increase the officially documented risk of abnormal bleeding.

In terms of pharmacokinetic interactions, the medicine is metabolized by the CYP450 enzyme system. Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole) increases the exposure (AUC and Cmax) of both Venlafaxine and its active metabolite. However, the regulatory label states that co-administration with only CYP2D6 inhibitors does not typically require a dose adjustment.

Restrictions extend to other substances: co-administration with alcohol should be avoided due to the potential for additive CNS effects and the risk of dose dumping with the extended-release formulation. Caution is also advised with St. John's Wort due to its serotonergic properties. Finally, official warnings note that reduced clearance in patients with hepatic or renal impairment may prolong drug exposure, potentially increasing the severity of these documented interactions.

Mechanism of Action

Selective alphavbeta3 Integrin Receptor Inhibition

Sesaren is an osteoclast inhibitor that demonstrates high affinity for the alphavbeta3 integrin receptor expressed on the osteoclast cell surface. Binding to the alphavbeta3 integrin is a necessary step for osteoclast attachment to the bone matrix, and inhibition of this binding prevents the formation of the ruffled border necessary for acid secretion and subsequent bone resorption.


Modulating Bone Remodeling Balance

The inhibition of osteoclast activity reduces bone resorption. This results in a net increase in bone mass relative to untreated states. Sesaren also modulates the expression of calcium-sensing receptors (CaSR) in parathyroid cells, a secondary pathway activity. The resulting shift in bone remodeling balance favors osteoblastic activity over osteoclastic activity.

Dosage and Administration Information

How to Use Sesaren: Official Administration Guidelines

Sesaren (Venlafaxine) is administered exclusively by the oral route (PO) and is available in extended-release (XR) forms, including capsules and tablets. This formulation is designed for once-daily use, which supports consistent plasma levels of the active ingredient throughout the day. To ensure the proper release mechanism is maintained, the extended-release tablet or capsule must be swallowed whole and must not be crushed, chewed, or divided.


Standard Dosing and Administration Schedule

Administration is required once daily with food, ideally taken at the same time each day. For conditions such as Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), the usual starting dose is 75 mg once daily, although some regimens may begin with 37.5 mg for a short introductory period. For most approved uses, the maximum recommended dose is 225 mg once daily. Dose adjustments should not be made more frequently than every 4 to 7 days, allowing for a gradual titration.


Usage Adjustments and Course Duration

Specific dosage modifications are required for certain patient groups. Patients with renal impairment (kidney function issues) or hepatic impairment (liver function issues) must receive a reduced total daily dose, often decreased by 25% to 50% or more. Treatment is typically continued for several months or longer for maintenance. The discontinuation of Sesaren requires a gradual dose reduction (tapering), commonly managed by reducing the daily amount in slow increments.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sesaren

This section summarizes the types of official research that have explored the use of Sesaren (Venlafaxine), detailing the research questions studied, the populations observed, and the areas where scientific certainty remains low. This overview is based on findings reported in controlled clinical trials and regulatory documents.


Evidence for Use in Major Depressive Disorder (MDD)

Research examining Sesaren was studied for Major Depressive Disorder (MDD) primarily relies on short-term randomized controlled trials (RCTs). These studies typically compare the medicine against a placebo over a defined time interval. Research examined outcomes related to symptom intensity or variability in adult outpatients. Findings from these trials describe patterns observed in the studies regarding symptom changes over the short observation period. However, follow-up durations were limited in many of the core acute studies, meaning the long-term effects are not fully established beyond the first few months.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Sesaren was studied for Generalized Anxiety Disorder (GAD) using both acute treatment trials and longer-term studies focused on preventing the return of symptoms. The research explored how symptoms change over time by tracking outcomes related to excessive worry, physical tension, and sleep disturbance in adult outpatients. Findings from these controlled settings describe patterns related to change in both the mental (psychic) and physical (somatic) components of anxiety. Evidence is limited regarding the differential effect of this treatment compared to all other standard medication classes for GAD.

Long-Term Studies and Durability of Effect

Beyond the initial short-term trials, research has explored the duration of symptom change using maintenance and relapse prevention studies over periods of up to 6 to 12 months. These studies report how symptoms evolved in the observed populations during this maintenance phase. The available data for these scenarios often apply only to the specific populations studied, and certainty regarding effects persisting significantly past the intermediate follow-up period remains low.

Research Gaps and What Remains Uncertain

Several areas remain where certainty remains low or where more research is needed, particularly regarding long-term effects on sustained functional recovery. Data for certain groups are limited, especially for pediatric and adolescent populations, as well as patients with significant concurrent medical or psychiatric conditions (complex comorbidities).

Key Studies & References

  1. Venlafaxine: U.S. National Library of Medicine (NIH) MedlinePlus Drug Information
  2. NICE Guideline NG222: Depression in adults: treatment and management

Frequently Asked Questions (FAQ)

Common questions about Sesaren (FAQ)


Q: Are there any common side effects people report when stopping Sesaren?

Official product information states that abruptly stopping Sesaren, or significantly reducing the dose, can lead to what are called discontinuation symptoms. Common effects reported include dizziness, headache, nausea, sleep disturbances (like vivid dreams), anxiety, and sensory disturbances, such as feeling electric-shock sensations. Official guidance suggests that patients should be aware of the possibility of these symptoms and discuss the proper way to reduce the dosage.


Q: Can caffeine or alcohol impact how Sesaren works?

Regulatory documents advise patients to avoid alcohol while taking Sesaren. This caution is in place because of the potential for compounded effects with alcohol. Official product information does not typically contain specific warnings or advice regarding caffeine intake.


Q: Is Sesaren safe to use during pregnancy according to official sources?

Using Sesaren during the third trimester of pregnancy may be associated with complications in the newborn shortly after delivery. These newborn complications include difficulties such as respiratory distress and feeding problems. Patients are advised to discuss pregnancy or pregnancy planning with their healthcare provider.


Q: What are the concerns for using Sesaren while breastfeeding?

Official information indicates that both Sesaren and its active metabolite (a substance the drug breaks down into) pass into breast milk. Caution is advised, and monitoring of infants, particularly newborns, is recommended for issues such as sedation, irritability, and adequate weight gain.


Q: What is the risk of an allergic reaction to Sesaren?

Official safety documents list hypersensitivity (allergic reaction) to Sesaren as an absolute contraindication, meaning anyone with a known allergy should not use the medicine. Patients who develop a rash, hives, or related allergic symptoms are advised to seek guidance from their physician.


Q: Are there certain foods or supplements that should be avoided with Sesaren? (Other than alcohol/St. John's Wort)

Official product information emphasizes the importance of discussing all medicines, herbal preparations, and nutritional supplements with a healthcare provider. This is because they may have potential interactions with Sesaren, such as increasing the risk of Serotonin Syndrome.


Q: What happens in the body when Sesaren stops working (after discontinuing)?

Pharmacokinetic data shows that Sesaren and its active metabolite are primarily eliminated from the body through the urine within about 48 hours. The abrupt absence of the drug's activity in the body is what can lead to the symptoms associated with discontinuation syndrome.


Q: How common are serious side effects with Sesaren?

Official documents list certain serious adverse reactions, such as seizures, lung problems, and severe skin reactions, that have been reported from postmarketing experience. Because these are reported outside of controlled studies, the precise frequency or commonness of these serious events is not precisely quantifiable in regulatory documents.


Q: Does Sesaren affect concentration or driving ability?

The official label includes a warning that Sesaren may impair a person's judgment, thinking, or motor skills. The label cautions against engaging in activities like operating hazardous machinery or driving, until the patient is certain the therapy does not adversely affect their ability.


Q: Are there different forms of Sesaren (e.g., tablet, liquid)?

Sesaren is officially available in solid oral dosage forms. This includes an immediate-release tablet and a long-acting extended-release capsule (or tablet), which are designed for different administration schedules.


Q: How quickly can a person expect Sesaren to start working?

Regulatory information related to how the drug works in the body indicates that steady-state concentrations (consistent levels in the bloodstream) of the drug and its active metabolite are generally achieved within 3 days of starting a regular dose. The timing of a patient's clinical effect is a separate, individual outcome.


Q: Is Sesaren known to cause weight changes?

Official safety data has specifically observed weight loss in pediatric patients (those aged 6 to 17) who take the drug. The clinical trials observed that a percentage of children experienced a measured loss of body weight.


Q: Are there any studies looking at the use of Sesaren in older adults?

The official regulatory label includes a dedicated section on use in Geriatric Patients (older adults). This section notes that older individuals may be at an increased risk for developing certain side effects, such as low sodium levels (hyponatremia), and may require dosage adjustments.


Q: Is Sesaren a controlled substance?

According to the U.S. Drug Enforcement Administration (DEA) and official prescribing information, Sesaren (venlafaxine) is not classified as a controlled substance under the U.S. Controlled Substances Act.


Q: What happens if a person forgets to take a dose of Sesaren?

For the immediate-release form, information generally advises that if a dose is missed, it can be taken as soon as it is remembered unless it is almost time for the next scheduled dose. For the extended-release form, specific instructions are usually provided by the prescriber regarding the handling of a missed dose.


Q: What should be done if a potential drug interaction is listed with Sesaren?

The regulatory label stresses the importance of informing a healthcare provider of all concomitant medications before starting Sesaren. The label warns never to take Sesaren with a Monoamine Oxidase Inhibitor (MAOI), as a potentially life-threatening interaction could occur.


Q: Is it possible to become dependent on Sesaren?

The product label includes a section on dependence, noting that abrupt discontinuation has been associated with discontinuation symptoms (or withdrawal-like symptoms). These effects can often be minimized by gradually reducing the dose over time, as guided by a physician.


Q: How long does Sesaren stay in the system after the last dose?

Pharmacokinetic data indicates that the drug and its active components have relatively short elimination times. The elimination half-life (the time it takes for half the dose to leave the body) for Sesaren is approximately 5 pm 2 hours and for its active metabolite is approximately 11 pm 2 hours in adults.


Q: What tests might a doctor require before starting Sesaren?

Patients should be monitored for sustained increases in blood pressure both before and during treatment. Additionally, official information suggests that monitoring serum cholesterol levels should be considered during long-term use, and an eye exam may be recommended due to the risk of angle-closure glaucoma in susceptible individuals.


Q: What is the purpose of the inactive ingredients in Sesaren?

The official product labeling lists all inactive ingredients used in the manufacturing of the drug. These components, such as cellulose or gelatin, are required to create the tablet or capsule form but are not detailed in regulatory documents regarding their specific purpose (such as binding or coloring).


Q: Can I use Sesaren if I have a heart condition?

The official label indicates that the drug may cause sustained increases in blood pressure and is associated with an increased heart rate. Patients should be monitored for these effects, which is particularly relevant for those with pre-existing heart conditions.

How should Sesaren be stored and disposed of?

Sesaren (venlafaxine) must be stored and handled according to specific regulatory conditions to maintain its quality and efficacy.

Official Storage Requirements

  • Temperature: Store at 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C.
  • Protection: Keep the medicine in its original container, tightly closed, and protect from moisture.
  • Child Safety: Store strictly out of the sight and reach of children.

Disposal Instructions

Expired or unused Sesaren should be disposed of via a drug take-back program if one is available locally. If no take-back program exists, the medicine must be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a plastic bag, and discarded with the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sesaren found in:

A-Z Index: